11 min read
Monthly FDA Guidance and Regulatory News Review - September 2026
This September 2026 regulatory update focuses on FDA’s new guidance on neonatal parenteral nutrition compounding and...
April 30, 2026 | Boston
⚛️ Where Clinical Strategy Meets Execution That Holds Up Under Scrutiny
On April 30, we will be attending the Precision Clinical Trials Summit Boston, where clinical development and operations leaders come together to address the complexities shaping modern trials. As study designs evolve and expectations for speed and precision increase, success depends on more than execution. It requires clear strategy, disciplined planning, and data that supports confident decisions at every stage.
Our team looks forward to meeting with biotech and clinical leaders to discuss how Veristat helps sponsors reduce rework, improve decision speed, and make every dollar of development capital count.
👥 Meet with Us at the Precision Clinical Trials Summit Boston
Connect with us to explore how Veristat’s scientific leadership and focused capabilities support confident decisions and efficient progress across clinical and regulatory milestones.
📅 Schedule a meeting in advance
Complete the form on this page to reserve time with Victor Zevallos, our Senior Business Development Director, to explore how Veristat can support your development strategy.
💡 Our Areas of Focus
Veristat’s work centers on the capabilities sponsors need most as programs move toward key development and regulatory milestones:
-
Phase I–II Clinical Development
-
Biostatistics and Data-Driven Evidence
-
Global Regulatory Strategy and Submissions
Together, these capabilities help sponsors move from study design to submission with clarity, reduce rework, and accelerate progress toward patients while preserving development capital.
Schedule A Meeting
Meet with Us at the Precision Clinical Trials Summit Boston
8 min read
Monthly FDA Guidance and Regulatory News Review - August 2026
Sep 21, 2026 Veristat Blog
This August 2026 regulatory update focuses on the FDA finalizing three guidances addressing formal sponsor meetings,...